Respiratory Syncytial Virus Prophylaxis – Global Drug Forecast and Market Analysis to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. RSV infection generally causes mild flu-like symptoms, which can include a runny nose, lowered appetite, fever, coughing, and/or sneezing. Irritability and difficulty breathing may be the only symptoms shown by very young infants with RSV. RSV is a viral infection that is transmitted through contact with droplets in the air or on surfaces like doorknobs, tabletops, and cribs, and through direct contact with the virus. Although RSV currently has neither a known cure nor a vaccine, preventive measures can be taken to help mitigate the spread of the disease. 

The RSV market is expected to experience significant growth over the forecast period (2020-2030) with the launches of numerous first-in-class products. The global prophylactic RSV market across the 8MM was valued at $454.8 million in 2020 and is expected to grow at an exponential CAGR of more than 30% over the 10-year forecast period. The RSV market’s growth is subjected to the launches of numerous first-in-class products.

The prophylactic market in the 8MM in 2020 consists of only one product-Sobi/AbbVie’s (formerly AstraZeneca’s) monoclonal antibody, Synagis (palivizumab). However, sales of Synagis are expected to drop substantially after the launch of competing passive prophylaxis products including AstraZeneca/Sanofi’s nirsevimab (MEDI-8897) and Merck’s clesrovimab (MK-1654).

Overview of global prophylactic RSV market

Overview of global prophylactic RSV market

For more insights on this report, download a free report sample

What are the key countries in the global prophylactic RSV market?

The US was the leading country in the market followed by the UK, Germany, France, Japan, Italy, Australia, and Spain.

Global prophylactic RSV market, by countries

Global prophylactic RSV market, by countries

For more country insights on this report, download a free report sample

What are the market dynamics of global prophylactic RSV market?

The global prophylactic RSV market is driven by the projected launch of AstraZeneca/Sanofi’s nirsevimab across the 8MM, the first vaccines to reach the market to prevent medically significant RSV infections in infants and older adults, and the expectation that a range of prophylactic products will be needed to address the diversity of infection in different patient populations.

There is currently only one FDA-approved preventative product on the market-Sobi/AbbVie’s monoclonal antibody, Synagis (palivizumab). Key opinion leaders (KOLs) have identified the dosing burden of five monthly injections during RSV season and the high cost of Synagis as major areas for improvement. These factors contribute to a limited recommendation issued by the American Academy of Pediatrics (AAP) that restricts its use to only the highest-risk premature infants, including those with conditions such as congenital heart disease (CHD) and chronic lung disease (CLD). The adult prophylaxis market currently has no products available and will also experience rapid growth with the launch of several vaccines for third-trimester pregnant women and adults 60 years of age and older. Due to the high level of competition in RSV prophylaxis, products will need to differentiate themselves using innovative therapeutic approaches.

What is the competitive landscape and opportunities of the global prophylactic RSV market?

The competitive landscape of RSV therapies is characterized by a high level of unmet needs and opportunities. Although nearly all individuals are infected by RSV by the end of their second year of life, infants who are premature, immunocompromised, or who have chronic lung or heart disease are more likely to develop severe lower respiratory tract infections (LRTIs) as a result of infection.

Despite a surge in R&D for RSV prophylactics and antivirals over the past decade, the field has produced significantly more disappointments than success stories. Synagis remains the only licensed intervention for the prevention of RSV in infants at high risk of severe infection, and there are no approved prophylactic agents for adults or otherwise healthy young children. The short half-life and high cost of Synagis continue to be a major barrier to its widespread clinical use despite its efficacy in high-risk infants. Synagis is not used in current practice as a therapeutic intervention for the treatment of existing RSV infections, which means that there are effectively no targeted treatment options for RSV in the 8MM. Ribavirin, although approved for the treatment of RSV infections in infants and adults, is rarely used as its clinical efficacy has not reliably been demonstrated.

Most individuals at risk for moderate or severe RSV infections do not currently have any prophylactic options available. Synagis is only recommended for certain high-risk pediatric patients due to its high cost. Because a significant number of infants hospitalized for RSV infections do not belong to any of the high-risk categories that are eligible for prophylaxis, they are therefore not targeted for prophylaxis during the RSV season.

Who are the major players in the global prophylactic RSV market?

In the global prophylactic RSV market, the major players include AstraZeneca, Sobi Inc., AbbVie Inc., and AIMM Therapeutics.

Market report scope

Market size (Year – 2020) $454.8 million
Growth rate CAGR of >30% from 2020 to 2030
Base year for estimation 2020
Forecast period 2020-2030
Key Countries The US, France, Spain, Germany, Italy, United Kingdom, Japan and Australia
Key players AstraZeneca, Sobi Inc., AbbVie Inc., AIMM Therapeutics, GlaxoSmithKline, Pfizer, Johnson & Johnson, Sanofi, Merck, and Bavarian Nordic

This report provides a comprehensive analysis of the global prophylactic RSV market. It provides:

  • Overview of RSV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline RSV prophylaxis market revenue from 2020-2030. The annual cost of therapy and major pipeline product sales in this forecast period are included.
  • Key topics covered include current RSV prophylaxis, unmet needs and opportunities, and the drivers and barriers affecting CHB treatment sales in the 8MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global RSV prophylaxis market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global RSV prophylactic market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the RSV prophylaxis market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

AstraZeneca Plc
Abbvie Inc.
Sobi Inc.
Merck & Co
Pfizer Inc.
Johnson & Johnson
Bavarian Nordic

Table of Contents

Table of Contents

| About GlobalData

1 Respiratory Syncytial Virus: Executive Summary

1.1 Strong Growth Projected for the RSV Market from 2020 to 2030

1.2 The Market for RSV Prophylaxis Is Untapped and Highly Competitive

1.3 Remaining Opportunities for Current and Future Players

1.4 Future RSV Management Strategies Will Include Multiple Products

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease Background

4.1.1 Risk Factors and Comorbidities

4.2 Global and Historical Trends

4.3 Forecast Methodology

4.3.1 Sources

4.3.2 Forecast Assumptions and Methods

4.4 Epidemiological Forecast for RSV Prophylactic Population (2020-2030)

4.4.1 Number of Preterm Births by Gestational Age

4.4.2 Preterm Infants with CLD

4.4.3 Number of Live Births with Hemodynamically Significant Heart Disease and Congenital Lung Disease

4.4.4 Diagnosed Prevalent Cases of DMD

4.4.5 Number of Diagnosed Prevalent Cases of SMA

4.4.6 Number of Third-Trimester Pregnant Women

4.4.7 Number of Adults Living in Nursing Homes/Long-Term Care Institutions

4.5 Discussion

4.5.1 Epidemiological Forecast Insight

4.5.2 COVID-19 Impact

4.5.3 Limitations of the Analysis

4.5.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved Passive Prophylaxis

7.3 Prophylactic Vaccines

7.4 Effective Therapeutic Antivirals

7.5 Increased Diagnostic Testing

7.6 Increased Research and Awareness of Long-Term Sequelae

8 R&D Strategies

8.1 Overview

8.1.1 Leveraging Novel Vaccine Technologies and Strategies

8.2 Clinical Trials Design

8.2.1 Clinical Trial Designs for RSV Vaccines for Maternal Immunization

8.2.2 Clinical Trials Designs for RSV Prophylactics for Pediatric Patients

8.2.3 Clinical Trials Design of Pipeline Prophylactics for Adult Immunization

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

12.5 Australia

12.5.1 Forecast

12.5.2 Key Events

12.5.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.3.2 Launch and Patent Expiry Dates

13.3.3 General Pricing Assumptions

13.3.4 Individual Drug Assumptions

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 Key Opinion Leaders

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Reviewers

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

13.7 Contact Us

Frequently asked questions

Respiratory Syncytial Virus Prophylaxis – Global Drug Forecast and Market Analysis to 2030 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Respiratory Syncytial Virus Prophylaxis – Global Drug Forecast and Market Analysis to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Respiratory Syncytial Virus Prophylaxis – Global Drug Forecast and Market Analysis to 2030 in real time.

  • Access a live Respiratory Syncytial Virus Prophylaxis – Global Drug Forecast and Market Analysis to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.